1. |
|
2. |
Araki T, Ishikawa H, Iwahashi C, et al. Central serous chorioretinopathy with and without steroids: a multicenter survey[J/OL]. PLoS One, 2019, 14(2): e213110[2019-02-28]. https://pubmed.ncbi.nlm.nih.gov/30818363/. DOI: 10.1371/journal.pone.0213110.
|
3. |
|
4. |
|
5. |
Kaye R, Chandra S, Sheth J, et al. Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities[J/OL]. Prog Retin Eye Res, 2020, 79: 100865[2020-05-11]. https://pubmed.ncbi.nlm.nih.gov/32407978/. DOI: 10.1016/j.preteyeres.2020.100865.
|
6. |
|
7. |
Clarke C, Smith SV, Lee AG. A rare association: Cushing disease and central serous chorioretinopathy[J/OL]. Can J Ophthalmol, 2017, 52(2): e77-e79[2016-10-27]. https://pubmed.ncbi.nlm.nih.gov/28457311/. DOI: 10.1016/j.jcjo.2016.09.002.
|
8. |
|
9. |
|
10. |
|
11. |
Takkar B, Temkar S, Gaur N, et al. Central serous retinopathy as presentation of an adrenal adenoma[J/OL]. BMJ Case Rep, 2018, 11(1): e227315[2018-12-14]. https://pubmed.ncbi.nlm.nih.gov/30567268/. DOI: 10.1136/bcr-2018-227315.
|
12. |
|